Giannis Mountzios/LinkedIn
May 11, 2025, 11:02
Giannis Mountzios: Can we quantify the harm-benefit ratio of adding chemo to IO in 1L advanced NSCLC?
Lung Cancer Europe shared a post by Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, on X, adding:
“Really useful real-world US data on chemo plus immunotherapy in 1st line NSCLC. Appreciate Giannis Mountzios’s insights – helps frame the bigger picture. Always important to ask not just if something works, but who it’s for, and what the impact is.”
Quoting Giannis Mountzios‘s post:
“Can we quantify the harm-benefit ratio of adding chemo to IO in 1L advanced NSCLC? Was a pleasure to be invited by JAMA Oncology to comment on the cohort study of 17 681 pts by Hayward et al from John Hopkins Medicine.”
Title: Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
Authors: James Heyward, Catherine R. Lesko, Joseph C. Murray, Hemalkumar B. Mehta, Jodi B. Segal
Journal: JAMA Oncology
Read Original Article.
Title: Immunotherapy With or Without Chemotherapy in Advanced NSCLC—A Delicate Balance of Harm and Benefit
Journal: JAMA Oncology
Author: Giannis Mountzios
Read Full Commentary.
More posts featuring NSCLC on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 11, 2025, 10:47
May 11, 2025, 10:32
May 11, 2025, 10:23
May 11, 2025, 09:27